Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease

Kevin Yau, Alexandra Kurtesi, Freda Qi, Melanie Delgado-Brand, Tulunay R. Tursun, Queenie Hu, Miten Dhruve, Christopher Kandel, Omosomi Enilama, Adeera Levin, Yidi Jiang, W. Rod Hardy, Darren A. Yuen, Jeffrey Perl, Christopher T. Chan, Jerome A. Leis, Matthew J. Oliver, Karen Colwill, Anne-Claude Gingras and Michelle A. Hladunewich ()
Additional contact information
Kevin Yau: University of Toronto
Alexandra Kurtesi: Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health
Freda Qi: Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health
Melanie Delgado-Brand: Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health
Tulunay R. Tursun: Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health
Queenie Hu: Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health
Miten Dhruve: Michael Garron Hospital
Christopher Kandel: Michael Garron Hospital
Omosomi Enilama: University of British Columbia
Adeera Levin: British Columbia Provincial Renal Agency
Yidi Jiang: Centre for Clinical Trial Support, Sunnybrook Research Institute
W. Rod Hardy: Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health
Darren A. Yuen: University of Toronto
Jeffrey Perl: University of Toronto
Christopher T. Chan: University of Toronto
Jerome A. Leis: University of Toronto
Matthew J. Oliver: University of Toronto
Karen Colwill: Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health
Anne-Claude Gingras: Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health
Michelle A. Hladunewich: University of Toronto

Nature Communications, 2023, vol. 14, issue 1, 1-8

Abstract: Abstract Neutralization of Omicron subvariants by different bivalent vaccines has not been well evaluated. This study characterizes neutralization against Omicron subvariants in 98 individuals on dialysis or with a kidney transplant receiving the BNT162b2 (BA.4/BA.5) or mRNA-1273 (BA.1) bivalent COVID-19 vaccine. Neutralization against Omicron BA.1, BA.5, BQ.1.1, and XBB.1.5 increased by 8-fold one month following bivalent vaccination. In comparison to wild-type (D614G), neutralizing antibodies against Omicron-specific variants were 7.3-fold lower against BA.1, 8.3-fold lower against BA.5, 45.8-fold lower against BQ.1.1, and 48.2-fold lower against XBB.1.5. Viral neutralization was not significantly different by bivalent vaccine type for wild-type (D614G) (P = 0.48), BA.1 (P = 0.21), BA.5 (P = 0.07), BQ.1.1 (P = 0.10), nor XBB.1.5 (P = 0.10). Hybrid immunity conferred higher neutralizing antibodies against all Omicron subvariants. This study provides evidence that BNT162b2 (BA.4/BA.5) and mRNA-1273 (BA.1) induce similar neutralization against Omicron subvariants, even when antigenically divergent from the circulating variant.

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-41678-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-41678-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-41678-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().